A phase II study of capecitabine plus oxaliplatin (XELOX): A new first-line option in metastatic colorectal cancer

International Journal of Gastrointestinal Cancer

Volumn 35, Issue 2, 2005, Pages 103-109

  Makatsoris, Thomas ^a   Kalofonos, Haralabos P ^b   Aravantinos, Gerasimos ^b   Papadimitriou, Christos ^b   Kastritis, Efstathios ^b   Rigatos, Sotirios K ^b   Xiros, Nikolaos ^b   Petsas, Theodore ^b   Economopoulos, Theofanis ^b   Sakadamis, Athanassios K ^b   Fountzilas, George ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b NONE

Author keywords

Capecitabine; Metastatic colorectal cancer; Oxaliplatin; XELOX

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; ARTICLE; COLORECTAL TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 24344440875     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:35:2:103     Document Type: Conference Paper

References (26)

1. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Schmoll H-J, Büchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999;26:589-605.
4. Thirion P, Wolmark N, Haddad E, Buyse M, Piedbois P. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol 1999;10:1317-1320.
5. Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 1998;34:1509-1513.
6. Pazdur R, Hoff PM, Medgyesy D, et al. The oral fluorouracil prodrugs. Oncology (Huntingt) 1998;12:48-51.
7. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
8. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297.
9. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 2002;38(Suppl 2):15-20.
10. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
11. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-1047.
12. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
13. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
14. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
15. Goldberg RM, Sargent DM, Fuchs CS, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
16. Sawada N, Tanaka Y, Twelves C, et al. Capecitabine plus oxaliplatin (XELOX): findings from a human colon cancer xenograft model and a phase II clinical trial in patients with metastatic colorectal cancer (MCRC). Eur J Cancer 2003;1(Suppl. 5):S93(Abstract 303).
17. Diaz-Rubio E, Evans TR, Tabernero, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13:558-565.
18. Blum JL, Smith SE, Buzbar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
21. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20:1759-1766.
22. Scheithauer W, Kornek G, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus Oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-1312.
23. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003;14:1378-1382.
24. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Oncol 2003;22:255 (abstract 1022).
25. Shields AF, Zalupski MM, Marshall JL, et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine : A phase II trial. Cancer 2004;100:531-537.
26. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091.